Tag Archive for: real-world data
Real-World Studies Suggest Survival Advantage with Apalutamide in mCSPC Treatment
/in Retrospective studies/by MaxRetrospective Study On Real World Data: Sipuleucel-T Shows Encouraging Results in mCRPC
/in Retrospective studies/by MaxReal-World Prostate Cancer Treatments Are Better Than Clinical Trial Results, Study Finds
/in Retrospective studies/by MaxASCO GU 2025: Lu-PSMA Therapy Outperforms Cabazitaxel in Advanced Prostate Cancer, Real-World Evidence
/in Retrospective studies/by MaxUndetectable PSA Nadir Linked to Better Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Real-World Data from IRONMAN Registry
/in Retrospective studies/by MaxASCO GU 2025: Impact of Homologous Recombination Repair Alterations on Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (BRCA, ATM, CDK12,…)
/in Observational, Retrospective studies/by MaxRetrospective study: Real-World Effectiveness of Apalutamide in mHSPC
/in Observational, Retrospective studies/by MaxApalutamide Shows Promising Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer: A Real-World Analysis
/in Observational, Post-hoc, Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- CRISPR Takes Another Step Forward September 14, 2026
- A STEAP1 ADC That May Turn Tumour Killing Into an Immune Response September 14, 2026
- Soon to be Phase 1 for ICP-B381, a New Bispecific Antibody-Drug Conjugate for mCPRC September 14, 2026
- Reprogramming Cancer, Decoding DNA: Two Promising New Frontiers in Cancer Research September 14, 2026